Brokers Offer Predictions for VKTX FY2025 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities researchers at B. Riley issued their FY2025 earnings estimates for shares of Viking Therapeutics in a research report issued on Thursday, October 23rd. B. Riley analyst W. Wood forecasts that the biotechnology company will post earnings of ($2.77) per share for the year. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. B. Riley also issued estimates for Viking Therapeutics’ Q4 2025 earnings at ($0.97) EPS, FY2026 earnings at ($3.72) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($3.03) EPS.

A number of other research analysts have also weighed in on VKTX. Raymond James Financial cut their target price on shares of Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a research report on Thursday, July 24th. BTIG Research reissued a “buy” rating and set a $125.00 target price on shares of Viking Therapeutics in a research report on Monday, September 22nd. Cantor Fitzgerald set a $105.00 target price on shares of Viking Therapeutics in a research report on Thursday. Morgan Stanley boosted their target price on shares of Viking Therapeutics from $98.00 to $102.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. cut their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Viking Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $85.62.

Viking Therapeutics Price Performance

Viking Therapeutics stock opened at $35.93 on Monday. The firm has a market cap of $4.06 billion, a price-to-earnings ratio of -16.95 and a beta of 0.64. Viking Therapeutics has a fifty-two week low of $18.92 and a fifty-two week high of $81.73. The firm has a fifty day moving average price of $28.44 and a two-hundred day moving average price of $28.92.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.14). The business’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the business earned ($0.22) EPS.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Allworth Financial LP raised its position in shares of Viking Therapeutics by 58.4% during the second quarter. Allworth Financial LP now owns 955 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 352 shares during the last quarter. Glass Jacobson Investment Advisors llc acquired a new position in shares of Viking Therapeutics during the second quarter valued at about $28,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Viking Therapeutics during the second quarter valued at about $29,000. Quarry LP raised its position in shares of Viking Therapeutics by 1,621.4% during the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,135 shares during the last quarter. Finally, Avion Wealth raised its position in shares of Viking Therapeutics by 1,157.0% during the third quarter. Avion Wealth now owns 1,521 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.